FDA Approves Obecabtagene Autoleucel for Adults with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukaemia By Ogkologos - December 3, 2024 892 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the FELIX study Source RELATED ARTICLESMORE FROM AUTHOR Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism EMA Recommends Extension of Indications for Ponatinib Associated with a New Pharmaceutical Form and a New Strength MOST POPULAR Όροι χρήσης και προϋποθέσεις January 18, 2019 9 Ways to Use Social Media for Support Throughout Your Cancer... February 4, 2021 New Task Force Focuses on Quality of Life for AYAs with... August 4, 2021 Synchronized Swimmer Learns She Has Breast Cancer After Teammate Kicks Her... March 4, 2020 Load more HOT NEWS FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer Pride 2023: Taking on the inequalities in LGBTQ+ cancer care New hormone treatment for advanced prostate cancer made available in England Dabrafenib–Trametinib Combination Approved for Melanoma, Anaplastic Thyroid Cancer
